<DOC>
	<DOCNO>NCT00380601</DOCNO>
	<brief_summary>An open-label , PhaseⅢ study evaluate efficacy safety MRA patient RA</brief_summary>
	<brief_title>PhaseⅢOpen-label Study MRA Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Diagnosed RA , basis criterion stipulate American Conference Rheumatism ( ACR ) 1987 Active RA despite least one DMARDs immunosuppressant Infliximab Etanercept.Active disease define least 6 tender 6 swollen joint among DAS28 ( Modified Disease Activity Scores include twenty eight joint count ) ESR least 30 mm/hr CRP le 2.0mg/dL Active RA despite 10mg adrenocortical steroid within 2 week entry study Shown classⅣ Steinbrocker 's functional activity evaluation carry within 4 week administration study drug Treated Infliximab within 3 month Etanercept within 2 week administration study drug Subjected follow within 4 week administration study drug : 1 . Surgical treatment ( operation , etc. ) . 2 . Plasma exchange method</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>